A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients.
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2017
At a glance
- Drugs AZD 1981 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms SWEAPEA
- Sponsors AstraZeneca
- 17 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 17 Sep 2010 New trial record